{"id":"W4415368586","doi":"10.1016/j.annonc.2025.10.006","title":"Patient-reported outcomes in the SERENA-6 trial of camizestrant plus CDK4/6 inhibitor in patients with advanced breast cancer and emergent ESR1 mutations during first-line endocrine-based therapy","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency","funders":"Takeda Oncology; Chugai Pharmaceutical; Weill Cornell Medical College; Daiichi Sankyo Company; Pfizer Japan; Unicancer; Ipsen; Eisai; Relay Therapeutics; Seagen; European Social Fund; Puma Biotechnology; Pfizer; Fondazione Internazionale Menarini; Genentech; Lilly Deutschland; Veracyte; Mersana Therapeutics; Helsinn; Les Laboratories Pierre Fabre; Menarini Silicon Biosystems; Friedrich-Alexander-Universität Erlangen-Nürnberg; Eisai Korea; Ipsen Biopharmaceuticals; F. Hoffmann-La Roche; Daiichi Sankyo Europe; Novartis Foundation; Gilead Sciences; Sanofi; Celgene; Universität Ulm; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Emory University","keywords":"Clinical trial; Disease; Breast cancer; Safety profile; MEDLINE","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001246726,0.0001900569,0.0006793498,0.0002779287,0.00003862269,0.00000254961,0.00007995099,0.00006496008,0.00002761014],"category_scores_gemma":[0.00006705748,0.0001239123,0.00007060023,0.0004115408,0.0001727266,0.00007737899,0.00002095389,0.0001738331,1.039338e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001039949,"about_ca_system_score_gemma":0.0004593497,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005743299,"about_ca_topic_score_gemma":0.001271857,"domain_scores_codex":[0.9984225,0.00009177727,0.000729856,0.0002535199,0.0002437811,0.0002585594],"domain_scores_gemma":[0.9988239,0.0002020733,0.0003847062,0.0002535509,0.0002925636,0.00004320354],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.1909062,0.003954507,0.687544,0.0002322465,0.0004177435,0.00007602242,0.001976055,0.005445114,0.000921569,0.00002832448,0.00001290592,0.1084853],"study_design_scores_gemma":[0.1492316,0.003529481,0.8419832,0.0003124095,0.0000437782,0.000006627241,0.0003970513,0.00003689259,0.003929697,0.00006715967,0.0003478332,0.0001143209],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9899072,0.00040781,0.00001586698,0.007776432,0.0001650006,0.001587112,0.0000804707,0.00001172621,0.00004837199],"genre_scores_gemma":[0.9985973,0.0002897129,0.0001472525,0.0005580483,0.00002304235,0.000327853,0.0000258362,0.00001491942,0.00001604321],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1544392,"threshold_uncertainty_score":0.5052994,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02773852152055462,"score_gpt":0.3571305366704038,"score_spread":0.3293920151498492,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}